TelyRx Surpasses 1 Million Prescriptions, Underscoring Growing Demand for Digital Pharmacy

Rhea-AI Summary

TelyRx (OTCQX:TELYF) announced it has surpassed 1 million prescriptions filled nationwide since inception, marking a key growth milestone for its digital, cash-pay pharmacy platform.

The company offers 450+ FDA-approved medications for 60+ conditions and says its infrastructure can serve over 97% of the U.S. population.

AI-generated analysis. Not financial advice.

Positive

• Surpassed 1 million prescriptions filled nationwide since inception
• Platform offers access to 450+ FDA-approved medications
• Covers treatment for 60+ acute and chronic conditions
• Operational infrastructure can serve over 97% of the U.S. population
• Reports strong repeat engagement across the platform
• Focus on compliance and clinical integrity by offering only FDA-approved, non-compounded, non-controlled medications

Negative

• None.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Milestone reflects strong customer response to simpler, more convenient access to essential healthcare

Clearwater, Florida--(Newsfile Corp. - June 8, 2026) - TelyRx Holdings Inc. (TSX: TELY) (OTCQX: TELYF), a technology-enabled healthcare and online pharmacy platform focused on expanding access to FDA-approved medications across the United States, today announced it has surpassed one million prescriptions filled nationwide since inception, a major milestone in the company's growth.

The milestone reflects growing consumer demand for healthcare experiences that are easier to navigate, more transparent, and more convenient as patients increasingly seek reliable access to everyday medications. To show appreciation, existing customers are being offered a sitewide discount and referral incentive to encourage others to choose TelyRx for their everyday care.

TelyRx is a cash-pay pharmacy platform that provides access to more than 450 FDA-approved medications. Through a fully integrated online experience, TelyRx helps patients access treatment for more than 60 acute and chronic health conditions, including allergies, asthma, diabetes, sexual health, women's and men's health, and common infections. By connecting patients with licensed healthcare providers and pharmacy services through a single online experience, TelyRx simplifies access to FDA-approved medications for routine care needs.

"Reaching one million prescriptions is a meaningful milestone for TelyRx and an opportunity to thank our customers," said Vanessa Slowey, President and CEO of TelyRx. "Consumers are looking for healthcare that is easier to access, simpler to navigate, and more reliable. The strongest signal for us is not the first prescription, it's that patients come back again and again."

TelyRx continues to see strong repeat engagement across the platform as more consumers incorporate direct-access healthcare into routine medication management. The company exclusively offers FDA-approved medications and does not offer compounded medications or controlled substances, reflecting its continued focus on compliance, clinical integrity, and patient trust.

The company's infrastructure is able to serve more than 97% of the U.S. population, and TelyRx continues expanding its physician network, pharmacy operations, and medication offerings nationwide to meet growing demand for more accessible, consumer-friendly healthcare experiences centered on convenience, consistency, and privacy.

About TelyRx

TelyRx is a technology-enabled healthcare and pharmacy services company operating a digital pharmacy platform connecting patients with independent, state-licensed providers to access over 450 everyday medications across 48 U.S. states and territories. The company fulfills prescriptions through its licensed retail pharmacies and offers fast, convenient delivery of medications directly to patients' doors.

For additional information, visit www.telyrx.com.

Forward-Looking Statements

This press release includes certain statements that may be deemed "forward‐looking statements". Forward‐looking statements are frequently, but not always, identified by words such as "expect", "anticipate", "estimate", "may", "could", "might", "will", "would", "should", "intend", "believe", "target", "budget", "plan", "strategy", "goals", "objectives", "predicts"; "potential", "projects", "possible", "milestones", "projection" or the negative of any of these words and similar expressions, although these words may not be present in all forward‐looking statements. Examples of forward-looking statements in this press release include, but are not limited to, statements regarding the potential growth in consumer demand for our services, consumer preferences and repeat engagement and the company's potential expansion of its physician network, pharmacy operations, and medication offerings nationwide.

Forward‐looking statements involve known and unknown risks, uncertainties, assumptions, and other factors that may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward‐looking statements. Such factors include, but are not limited to, the factors discussed in the section entitled "Risk Factors" in the management discussion and analysis of the Company dated May 12, 2026 and filed on SEDAR+. Although the Company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward‐looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated or intended. Forward-looking statements contained herein are made as of the date hereof and, other than as required by law, the Company disclaims any obligation to update any forward‐looking statements, whether because of new information, future events, or results or otherwise. There can be no assurance that forward‐looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward‐looking statements are based on several assumptions, which may prove to be incorrect, including but not limited to the assumptions discussed in this section. Accordingly, readers should not place undue reliance on forward‐looking statements.

Media Contacts:

Antonia Graham
TelyRx Corporate Affairs
antonia.graham@telyrx.com

Havas Red
TelyRxPress@havasred.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/300445

FAQ

What milestone did TelyRx (OTCQX:TELYF) report on June 8, 2026?

TelyRx announced it has surpassed one million prescriptions filled nationwide since inception. According to TelyRx, this milestone reflects strong consumer adoption of its digital, cash-pay pharmacy model for accessing FDA-approved medications and integrated telehealth and pharmacy services across the United States.

What types of medications does TelyRx (TELYF) provide through its digital pharmacy platform?

TelyRx provides access to more than 450 FDA-approved medications on a cash-pay basis. According to TelyRx, these medicines cover over 60 acute and chronic conditions, including allergies, asthma, diabetes, sexual health, women’s and men’s health, and common infections via a fully online experience.

How much of the U.S. population can TelyRx (TELYF) currently serve?

TelyRx reports its infrastructure can serve more than 97% of the U.S. population. According to TelyRx, the company is expanding its physician network, pharmacy operations, and medication offerings nationwide to meet rising demand for convenient, consumer-friendly, direct-access healthcare and medication management.

Does TelyRx (TELYF) dispense compounded medications or controlled substances?

TelyRx states it exclusively offers FDA-approved medications and does not provide compounded medications or controlled substances. According to TelyRx, this approach supports a focus on compliance, clinical integrity, and building patient trust within its nationwide digital pharmacy and telehealth platform.

How does TelyRx’s (TELYF) digital pharmacy model work for patients?

TelyRx connects patients with licensed healthcare providers and pharmacy services through one online experience. According to TelyRx, this integrated, cash-pay platform simplifies access to FDA-approved medications for routine care needs, emphasizing ease of navigation, transparency, convenience, and privacy for everyday prescription management.

What evidence does TelyRx (TELYF) cite of repeat usage on its platform?

TelyRx reports strong repeat engagement from patients using its digital pharmacy services. According to TelyRx, an important signal of demand is that patients return for additional prescriptions, not just their first order, as they incorporate direct-access healthcare into routine medication management.